[go: up one dir, main page]

DK0431129T3 - Fremgangsmåder til inaktivering af virus i viruskontaminerede farmaceutiske præparater - Google Patents

Fremgangsmåder til inaktivering af virus i viruskontaminerede farmaceutiske præparater

Info

Publication number
DK0431129T3
DK0431129T3 DK90909877.4T DK90909877T DK0431129T3 DK 0431129 T3 DK0431129 T3 DK 0431129T3 DK 90909877 T DK90909877 T DK 90909877T DK 0431129 T3 DK0431129 T3 DK 0431129T3
Authority
DK
Denmark
Prior art keywords
plasma
virus
methods
pharmaceutical compositions
blood product
Prior art date
Application number
DK90909877.4T
Other languages
Danish (da)
English (en)
Inventor
Michael E Hrinda
Rose Dalisa
George Crissman Tarr
Original Assignee
Rorer Int Overseas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rorer Int Overseas filed Critical Rorer Int Overseas
Application granted granted Critical
Publication of DK0431129T3 publication Critical patent/DK0431129T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088—Liquid substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
DK90909877.4T 1989-06-15 1990-06-13 Fremgangsmåder til inaktivering af virus i viruskontaminerede farmaceutiske præparater DK0431129T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36685589A 1989-06-15 1989-06-15

Publications (1)

Publication Number Publication Date
DK0431129T3 true DK0431129T3 (da) 1996-06-17

Family

ID=23444851

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90909877.4T DK0431129T3 (da) 1989-06-15 1990-06-13 Fremgangsmåder til inaktivering af virus i viruskontaminerede farmaceutiske præparater

Country Status (9)

Country Link
US (1) US5300433A (es)
EP (1) EP0431129B1 (es)
JP (1) JP3297433B2 (es)
AT (1) ATE138575T1 (es)
CA (1) CA2034489C (es)
DE (1) DE69027187T2 (es)
DK (1) DK0431129T3 (es)
ES (1) ES2087156T3 (es)
WO (1) WO1990015613A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
AT408191B (de) * 1991-08-19 2001-09-25 Haemosan Erzeugung Pharmazeuti Verfahren zur inaktivierung von prionen
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
WO1994013329A1 (de) * 1992-12-16 1994-06-23 Immuno Aktiengesellschaft Verfahren zur herstellung eines virussicheren biologischen präparates
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
DE4434538C2 (de) * 1993-10-06 2000-08-10 Immuno Ag Verfahren zur Virusinaktivierung in Gegenwart eines Polyethers und eines chaotropen Agens
HRP940645A2 (en) * 1993-10-06 1996-12-31 Immuno Ag Process for virus deactivation in the presence of polyalkylene glycol and the pharmaceutical preparation thus obtained
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AU693354B2 (en) * 1995-04-10 1998-06-25 Baxter International Inc. The use of cross-linked hemoglobin in treating subarachnoid hemorrhage
US5741894A (en) * 1995-09-22 1998-04-21 Baxter International, Inc. Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
US6005077A (en) * 1995-11-10 1999-12-21 Immuno Aktiengesellschaft Use of von willebrand factor and pharmaceutical formulation
US7026468B2 (en) * 1996-07-19 2006-04-11 Valentis, Inc. Process and equipment for plasmid purification
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
UA64742C2 (uk) * 1997-12-24 2004-03-15 Альфа Терапевтик Корпорейшн СПОСІБ ОДЕРЖАННЯ РОЗЧИНУ <font face="Symbol">g</font>-ГЛОБУЛІНУ, ПРИЗНАЧЕНОГО ДЛЯ ВНУТРІШНЬОВЕННОГО ВВЕДЕННЯ, І ПРОДУКТ, ЩО ОДЕРЖУЄТЬСЯ У ЦЕЙ СПОСІБ (ВАРІАНТИ)
US6270723B1 (en) * 1998-06-15 2001-08-07 Bbi Bioseq, Inc. Rapid cryobaric sterilization and vaccine preparation
US6441144B1 (en) 1999-05-20 2002-08-27 Alpha Therapeutic Corporation Method for repairing dual virally inactivated immune globulin for intravenous administration
US6747132B2 (en) 2000-11-29 2004-06-08 Apex Biosciences, Inc. Methods for the synthesis of a modified hemoglobin solution
US7038016B2 (en) 2001-08-21 2006-05-02 Apex Bioscience, Inc. Methods for purification of an activated PEG solution and for the synthesis of a modified hemoglobin solution
CA2476999C (en) * 2002-02-22 2015-09-15 Intracel Resources Llc Sterile immunogenic non-tumorigenic tumor cell compositions and methods
EP1554398A4 (en) * 2002-09-13 2005-12-14 Valentis Inc DEVICE AND METHOD FOR THE CLEANING OF NUCLEAR SULFUR IN THE PREPARATIVE SCALE
EP1729797B1 (en) * 2004-03-22 2008-09-10 Solvay Pharmaceuticals GmbH Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
WO2006023774A2 (en) * 2004-08-20 2006-03-02 Imquest Biosciences, Inc. Plasma or serum fraction for treatment and prevention of viral infections and related conditions
HUE031042T2 (en) 2005-07-29 2017-06-28 Abbott Laboratories Gmbh Methods for producing pancreatin powder with low viral content
US9198871B2 (en) * 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
EP3187585A1 (en) 2010-03-25 2017-07-05 Oregon Health&Science University Cmv glycoproteins and recombinant vectors
WO2012069474A2 (en) * 2010-11-24 2012-05-31 H. Lundbeck A/S A method for reducing potential virus burden in a sample by cyanate treatment
US9488625B2 (en) 2010-12-15 2016-11-08 Baxalta GmbH Purification of factor VIII using a conductivity gradient
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
EP2848937A1 (en) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Methods of identifying novel HIV-1 immunogens
EP2873423B1 (en) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (en) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Soluble hiv-1 envelope glycoprotein trimers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2475572A1 (fr) * 1980-02-11 1981-08-14 Pasteur Institut Procede pour l'obtention de fragments de virus a enveloppe lipidique, en particulier d'antigenes utilisables comme vaccins, produits obtenus et applications
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
EP0162078B1 (en) * 1983-10-28 1994-09-14 New England Medical Center Hospitals, Inc. Method for isolating a protein from a mixture containing said protein and a conformation specific antibody useful therein
US4673733A (en) * 1985-04-11 1987-06-16 Sudhish Chandra Treatment of biological and pharmaceutical products adsorbed on a solid phase with virus and pyrogen inactivating agents
AT385203B (de) * 1985-04-26 1988-03-10 Immuno Ag Verfahren zur herstellung einer fruehsommermeningoenzephalitis-virus (fsme-virus)-vakzine
US4732683A (en) * 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
DD264137A1 (de) * 1987-09-22 1989-01-25 Univ Leipzig Mittel zur bekaempfung von viren in kulturpflanzen

Also Published As

Publication number Publication date
EP0431129A1 (en) 1991-06-12
JP3297433B2 (ja) 2002-07-02
JPH04501429A (ja) 1992-03-12
EP0431129B1 (en) 1996-05-29
ATE138575T1 (de) 1996-06-15
CA2034489C (en) 1996-07-16
WO1990015613A1 (en) 1990-12-27
DE69027187D1 (de) 1996-07-04
US5300433A (en) 1994-04-05
EP0431129A4 (en) 1992-03-11
ES2087156T3 (es) 1996-07-16
DE69027187T2 (de) 1996-10-31
CA2034489A1 (en) 1990-12-16

Similar Documents

Publication Publication Date Title
DK0431129T3 (da) Fremgangsmåder til inaktivering af virus i viruskontaminerede farmaceutiske præparater
ATE54828T1 (de) Behandlung von auf einer festen phase adsorbierten biologischen und pharmazeutischen produkten mit viren und pyrogenen inaktivierenden agenzien.
DK552684A (da) Desulfatohirudiner samt deres fremstilling og anvendelse
ATE231549T1 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
FI961536A0 (fi) Menetelmä virusten inaktivoimiseksi polyalkeeniglykolin läsnäollessa samoin kuin siten saatu farmaseuttinen valmiste
KR950010898A (ko) 재조합 사람 혈청 알부민 약제학적 제제의 멸균법
NO20013918D0 (no) Fremgangsmate for a inaktivere patogener ved anvendelse av bredspektret pulset lys
ATE189394T1 (de) Methode zur behandlung von viralen infektionen
ES2113910T3 (es) Procedimiento para la preparacion de un concentrado de trombina asegurado contra virus.
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
FI953756A0 (fi) Menetelmä lipidivaipattomien virusten inaktivoimiseksi
ATE298582T1 (de) Verfahren zur inaktivierung von viren und lyophilisierung von blutproteinen
Blajchman Protecting the blood supply from emerging pathogens: the role of pathogen inactivation
ES2149791T3 (es) Procedimiento para la inactivacion de virus en preparaciones de proteinas.
DK0653939T3 (da) Anvendelse af en Hymenoptera-gift til fremstilling af et medikament til behandling af DNA-virusinfektioner
DE60229924D1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
EP0686694A1 (en) Use of azoles as virucidal agents in solutions of biologically active proteins
Clark et al. Strategy for purification of coagulation factor concentrates
FI93696B (fi) Kymotrypsiinin käyttö prekallikreiini-aktivaattorin tehottamiseksi tekemiseksi
Gröner et al. Purity, activity, and virus safety of a pasteurized antithrombin concentrate
ATE196424T1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
ATE100318T1 (de) Verwendung von chinolyl- und isochinolyloxazol-2- onen zur herstellung eines arzneimittels zur verhinderung der ansteckungsfaehigkeit von mit glykoproteinen umhuellten viren.
EP1021209A1 (en) Inactivation of viruses by incubation with caprylate
KR970042591A (ko) 트레할로스를 안정제로 이용한 단백질용액의 액상가열처리방법
AU5111598A (en) Inactivation of viruses by incubation with caprylate